Abbreviations
toxicity, sarcoma, survivalprogrammed, tumour
METASTATIC LUNG CANCER, LUNG CANCER, SARCOMA, TUMOUR, DELETION, LYMPHOMA
The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non‐small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in patients (Immunotherapy has transformed the treatment landscape of advanced non‐small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable responses to these drugs and to help monitor the treatment effect. In this clinical trial, we investigated the tolerability, efficacy and circulating tumour DNA responses in patients with metastatic lung cancer treated with atezolizumab combined with radiotherapy.allele frequencyanaplastic lymphoma kinasebiologically effective dosecell‐free DNAcell‐free nucleic acidcopy number variantscomplete responsecommon terminology criteria for adverse eventscirculating tumour DNAethylenediaminetetraacetic acidepidermal growth factor receptorerythroblastic oncogene Bformalin‐fixed paraffin‐embeddedgross tumour volumeimmune checkpoint inhibitorinsertion–deletion mutationsKirsten rat sarcoma viral oncogene homologlimit of detectionmesenchymal–epithelial transition factornot evaluablenanogramnext‐generation sequencingnon‐small‐cell lung cancerobjective response rateoverall survivalprogrammed cell death protein‐1programmed death‐ligand 1progression‐free survivalpartial responseperformance statusplanning target volumeradiotherapystereotactic body radiotherapystable diseasesingle nucleotide variants